Hormone receptor positive breast cancer
Not recruitingStudy of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy
Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy
- Disease:Hormone receptor positive breast cancer
- Substances:AnastrozoleExemestane+5
Belgium- Participants:18–64 years · 65+ years
- Substances:Anastrozole
- Sponsor:Olema Pharmaceuticals Inc.












